Literature DB >> 1349353

Cellular basis for interactions between catecholaminergic afferents and neurons containing Leu-enkephalin-like immunoreactivity in rat caudate-putamen nuclei.

V M Pickel1, J Chan, S R Sesack.   

Abstract

Dopaminergic afferents to the dorsal striatum, caudate-putamen nuclei, are known to modulate the levels and synthesis of endogenous opiate peptides (Leu5 and Met5-enkephalins). We examined the dual immunocytochemical localization of antisera raised against Leu5-enkephalin and the catecholamine-synthesizing enzyme, tyrosine hydroxylase (TH), to determine the cellular substrates for these and/or other functional interactions. The antisera were identified by combined immunogold-silver and immunoperoxidase labeling in single coronal sections through the caudate-putamen nuclei of adult rats. These animals were given intraventricular injections of colchicine, and the brains were fixed by acrolein perfusion prior to immunocytochemical labeling. By light microscopy, perikarya and processes containing enkephalin-like immunoreactivity (ELI) were seen in close proximity to varicose processes immunoreactive for TH. Electron microscopy further demonstrated that the ELI was localized to perikarya, dendrites, and axon terminals, whereas the TH was exclusively in axons and terminals. The dendrites containing ELI were postsynaptic to terminals that were either (1) without detectable immunoreactivity, or (2) immunoreactive for TH or enkephalin. Nonsynaptic portions of the dendrites containing ELI were covered with astrocytic processes or were in direct apposition to unlabeled dendrites. Terminals containing ELI were densely immunoreactive and were in direct contact with (1) unlabeled and occasionally enkephalin-labeled proximal dendrites, and (2) TH-labeled and unlabeled terminals. In comparison with the opiate terminals, most catecholaminergic terminals were lightly immunoreactive for TH and usually contacted more distal unlabeled dendrites or spines and, more rarely, dendrites containing ELI. In a few favorable planes of section, the terminals containing ELI and those containing TH (1) converged on common unlabeled dendrites, or (2) formed dual contacts on two different labeled or unlabeled targets. Junctions formed by terminals containing ELI and TH were sometimes characterized by symmetric synaptic densities. However, numerous other dendritic and all axonal appositions were without recognized membrane densities. The findings of the study provide anatomical substrates for multilevel interactions between catecholamines, mostly dopamine, and enkephalin in rat dorsal striatum. These include (1) monosynaptic input from dopaminergic terminals to neurons containing enkephalin, (2) presynaptic modulation of transmitter release through axonal appositions, and (3) dual regulation of common targets through convergent input. In addition, the findings suggest that both enkephalin and dopamine may have similar modulatory roles in synchronizing the activity of dual targets postsynaptic to individual axon terminals. Alterations in any one of these multiple types of interactions could account for noted motor or sensory symptoms in neurological disorders characterized by depletion of dopamine or endogenous opiate peptides, or both.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349353     DOI: 10.1002/jnr.490310203

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  11 in total

Review 1.  Synaptic organisation of the basal ganglia.

Authors:  J P Bolam; J J Hanley; P A Booth; M D Bevan
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

2.  Opiate agonist-induced re-distribution of Wntless, a mu-opioid receptor interacting protein, in rat striatal neurons.

Authors:  B A S Reyes; K Vakharia; T N Ferraro; R Levenson; W H Berrettini; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

3.  Involvement of the rat caudate nucleus in the immunostimulatory effect of DAGO.

Authors:  L V Devoino; M A Cheido; E L Al'perina
Journal:  Neurosci Behav Physiol       Date:  2001 May-Jun

Review 4.  Direct and indirect pathways of basal ganglia: a critical reappraisal.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Veronica Ghiglieri; Massimiliano Di Filippo
Journal:  Nat Neurosci       Date:  2014-07-28       Impact factor: 24.884

5.  Ultrastructural relationship between the mu opioid receptor and its interacting protein, GPR177, in striatal neurons.

Authors:  Arith-Ruth S Reyes; Robert Levenson; Wade Berrettini; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2010-09-21       Impact factor: 3.252

6.  Heteromers of μ opioid and dopamine D1 receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner.

Authors:  Yi-Min Tao; Chuan Yu; Wei-Sheng Wang; Yuan-Yuan Hou; Xue-Jun Xu; Zhi-Qiang Chi; Yu-Qiang Ding; Yu-Jun Wang; Jing-Gen Liu
Journal:  Br J Pharmacol       Date:  2017-07-18       Impact factor: 8.739

7.  Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors.

Authors:  L Churchill; B P Roques; P W Kalivas
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

8.  Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley; Adrienne C Lahti
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

9.  Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat.

Authors:  Shane A Perrine; Imran S Sheikh; Chinwe A Nwaneshiudu; Joseph A Schroeder; Ellen M Unterwald
Journal:  Neuropharmacology       Date:  2007-10-22       Impact factor: 5.250

10.  Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements.

Authors:  Hélène N David
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.